Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Andrew Rowland, Mafalda Dias, Michael Wiese, Ganessan Kichenadasse, Ross McKinnon, Christos Karapetis, Michael Sorich

    Research output: Contribution to journal › Article › peer-review

    265 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science